— Know what they know.
Not Investment Advice
Also trades as: NVV1.F (FSX) · $vol 0M

NVAX NASDAQ

Novavax, Inc.
1W: -12.3% 1M: -7.2% 3M: +36.5% YTD: +40.5% 1Y: +17.6% 3Y: +55.8% 5Y: -93.8%
$10.02
+0.62 (+6.60%)
 
Weekly Expected Move ±16.8%
$6 $8 $10 $11 $13
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 33 · $1.7B mcap · 146M float · 3.80% daily turnover · Short 51% of daily vol
Credit Risk of going bust: higher than 67% of companies Debt: 16.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.23 (down 98%), Novavax, Inc. would be worth roughly what it owes.
Total debt $295.6M against a stock market value of $1.55B.
Distance to default 3.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $144.9M (short-term plus half of long-term), stock volatility 68.7%; Altman Z'' -14.52. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.7B
52W Range6.2-13.39
Volume6,766,791
Avg Volume5,559,934
Beta2.44
Dividend—
Analyst Ratings
16 Buy 3 Hold 4 Sell
Consensus Buy
Company Info
CEOJohn Charles Jacobs
Employees749
SectorHealthcare
IndustryBiotechnology
IPO Date1995-12-05
21 Firstfield Road
Gaithersburg, MD 20878
US
240 268 2000
About Novavax, Inc.

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
Rodgers Richard J M-Exempt 18,880 — 2026-06-20
Rodgers Richard J M-Exempt 18,880 — 2026-06-20
King Rachel K. M-Exempt 18,880 — 2026-06-20
King Rachel K. M-Exempt 18,880 — 2026-06-20
DOUGLAS RICHARD M-Exempt 18,880 — 2026-06-20

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms